<h1>Manufacturer launches next-generation continuous glucose monitor for ages 2+, one-minute readings, alerts, smartphone connectivity; legal and safety risks</h1> A medical-device manufacturer announced the national launch of a next-generation continuous glucose monitor offering automatic one-minute readings, optional alerts and smartphone connectivity, marketed for adults and children from age two including gestational diabetes. The release emphasizes claimed clinical benefits supported by cited studies and refers to regulatory classifications and compatibility limitations; it also notes conditions (e.g., rapidly changing glucose) requiring confirmatory finger-prick testing. Legal considerations include accuracy and labeling claims, conformity with applicable device regulations and interoperability standards, advertising and reimbursement representations, data privacy and cloud-sharing features, and potential product liability exposure if performance or instructions differ from promotional statements or regulatory approvals.